Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 286

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

Open access
Kelly, Richard J., Höchsmann, Britta, Szer, Jeff, Kulasekararaj, Austin, de Guibert, Sophie, Röth, Alexander, Weitz, Ilene C., Armstrong, Elina, Risitano, Antonio M., Patriquin, Christopher J., Terriou, Louis, Muus, Petra, Hill, Anita, Turner, Michelle P., Schrezenmeier, Hubert, Peffault de Latour, Regis·2015·New England Journal of Medicine

Abstract

BACKGROUND: Eculizumab, a humanized monoclonal antibody against complement protein C5 that inhibits terminal complement activation, has been shown to prevent complications of paroxysmal nocturnal hemoglobinuria (PNH) and improve quality of life and overall survival, but data on the use of eculizumab in women during pregnancy are scarce. METHODS: We designed a questionnaire to solicit data on pregnancies in women with PNH and sent it to the members of the International PNH Interest Group and to the physicians participating in the International PNH Registry. We assessed the safety and efficacy of eculizumab in pregnant patients with PNH by examining the birth and developmental records of the children born and adverse events in the mothers. RESULTS: Of the 94 questionnaires that were sent out, 75 were returned, representing a response rate of 80%. Data on 75 pregnancies in 61 women with PNH were evaluated. There were no maternal deaths and three fetal deaths (4%). Six miscarriages (8%) occurred during the first trimester. Requirements for transfusion of red cells increased during pregnancy, from a mean of 0.14 units per month in the 6 months before pregnancy to 0.92 units per month during pregnancy. Platelet transfusions were given in 16 pregnancies. In 54% of pregnancies that progressed past the first trimester, the dose or the frequency of use of eculizumab had to be increased. Low-molecular-weight heparin was used in 88% of the pregnancies. Ten hemorrhagic events and 2 thrombotic events were documented; both thrombotic events occurred during the postpartum period. A total of 22 births (29%) were premature. Twenty cord-blood samples were examined for the presence of eculizumab; the drug was detected in 7 of the samples. A total of 25 babies were breast-fed, and in 10 of these cases, breast milk was examined for the presence of eculizumab; the drug was not detected in any of the 10 breast-milk samples. CONCLUSIONS: Eculizumab provided benefit for women with PNH during pregnancy, as evidenced by a high rate of fetal survival and a low rate of maternal complications. (ClinicalTrials.gov number, NCT01374360.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1502950

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 286

Metadata

Authors
Kelly, R. J., Höchsmann, B., Szer, J., Kulasekararaj, A., de Guibert, S., Röth, A., Weitz, I. C., Armstrong, E., Risitano, A. M., Patriquin, C. J., Terriou, L., Muus, P., Hill, A., Turner, M. P., Schrezenmeier, H., & Peffault de Latour, R.
Venue
New England Journal of Medicine
Published
2015-09-10
Volume
373
Issue
11
Pages
1032-1039
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2335653426
Cited by
286
References
19
FWCI
10.58
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. https://app.cochat.ai/papers/10.1056/nejmoa1502950
The paper
Kelly, R. J., Höchsmann, B., Szer, J., Kulasekararaj, A., de Guibert, S., Röth, A., Weitz, I. C., Armstrong, E., Risitano, A. M., Patriquin, C. J., Terriou, L., Muus, P., Hill, A., Turner, M. P., Schrezenmeier, H., & Peffault de Latour, R. (2015). Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1502950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.